CelLBxHealth plc (LSE:CLBX) has entered into a collaboration and co-marketing agreement with QIAGEN Manchester Ltd., a move aimed at strengthening the development of CTC-based applications. The partnership will integrate CelLBxHealth’s Parsortix platform with QIAGEN’s molecular technologies to support drug development, biomarker discovery, and companion diagnostic feasibility work. Under the agreement, QIAGEN can promote the Parsortix system to its pharmaceutical partners, potentially accelerating broader adoption of liquid-biopsy-driven approaches in oncology. The initiative fits squarely within CelLBxHealth’s strategy to expand global access to its CTC technology and deepen its presence in precision medicine.
CelLBxHealth’s broader outlook continues to be overshadowed by weak financial performance and valuation pressures, with technical indicators pointing to bearish trading conditions. Although management has highlighted some positive operational developments, ongoing funding needs and difficult market dynamics remain key challenges for the company.
More about CelLBxHealth plc
CelLBxHealth plc is a global precision CTC intelligence company specialising in circulating tumour cell technologies for research, drug development, and clinical oncology. Its patented Parsortix® platform captures CTCs from blood and integrates seamlessly with standard laboratory workflows, enabling whole-cell imaging, proteomic analysis, and comprehensive genomic profiling. The company focuses on product sales, lab-developed tests, and specialised laboratory services, with commercial efforts aimed at accelerating adoption of Parsortix and supporting clinical trials and assay development.









